Analyst Price Targets — BMRN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 3, 2026 11:12 am | Eliana Merle | Barclays | $105.00 | $59.74 | StreetInsider | BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Barclays |
| March 2, 2026 2:53 pm | Ilya Zubkov | Loop Capital Markets | $105.00 | $60.47 | StreetInsider | BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Freedom Capital Markets |
| February 26, 2026 1:22 pm | Whitney Ijem | Canaccord Genuity | $104.00 | $60.26 | StreetInsider | BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $104 at Canaccord |
| February 24, 2026 12:48 pm | — | Oppenheimer | $95.00 | $62.92 | TheFly | BioMarin price target lowered to $95 from $98 at Oppenheimer |
| February 24, 2026 11:48 am | Paul Matteis | Stifel Nicolaus | $68.00 | $61.44 | StreetInsider | BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $68 at Stifel |
| February 18, 2026 11:23 am | — | Wells Fargo | $75.00 | $59.95 | TheFly | BioMarin price target raised to $75 from $70 at Wells Fargo |
| February 6, 2026 11:51 am | — | Piper Sandler | $84.00 | $57.15 | TheFly | BioMarin price target lowered to $84 from $122 at Piper Sandler |
| January 20, 2026 10:05 am | — | Canaccord Genuity | $98.00 | $54.59 | TheFly | BioMarin upgraded to Buy from Hold at Canaccord |
| December 23, 2025 12:38 pm | Joon Lee | Truist Financial | $100.00 | $59.28 | TheFly | BioMarin price target raised to $100 from $80 at Truist |
| December 22, 2025 11:12 am | — | H.C. Wainwright | $60.00 | $61.15 | TheFly | BioMarin price target raised to $60 from $55 at H.C. Wainwright |
Latest News for BMRN
The FDA approved BioMarin's supplemental BLA for Palynziq, a treatment for PKU in adolescents 12 and older.
Envestnet Asset Management Inc. trimmed its position in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 50.4% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,167 shares of the biotechnology company's stock after selling 25,586 shares during the quarter. Envestnet Asset
Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS study PALYNZIQ is the only enzyme substitution therapy approved for the treatment of people with PKU SAN RAFAEL, Calif., Feb. 27, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the…
DNB Asset Management AS increased its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 13.8% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 1,274,284 shares of the biotechnology company's stock after purchasing an additional 154,954 shares during the period. DNB Asset Management AS
BioMarin beats Q4 earnings estimates as Voxzogo drives year-over-year revenue growth. The company decides to voluntarily withdraw its hemophilia gene therapy.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BMRN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.